Table 2
| Â | Ph-like | Â | ||
|---|---|---|---|---|
Characteristic | Overall, N = 197 | Yes, N = 58 | No, N = 139 | p-value |
Sex, n (%) | Â | Â | Â | 0.35 |
 M | 111 (56%) | 36 (62%) | 75 (54%) |  |
 F | 86 (44%) | 22 (38%) | 64 (46%) |  |
Age, median (range) | 40 (18, 65) | 39 (18, 65) | 40 (18, 65) | 0.65 |
WBC, n (%) | Â | Â | Â | 0.001 |
 WBC > 30 × 10^−9/L | 54 (28%) | 25 (45%) | 29 (21%) |  |
 WBC < 30 × 10^−9/L | 140 (72%) | 31 (55%) | 109 (79%) |  |
Risk, n (%) | Â | Â | Â | 0.091 |
 SR | 120 (64%) | 28 (54%) | 92 (68%) |  |
 NO SR | 68 (36%) | 24 (46%) | 44 (32%) |  |
All category, n (%) | Â | Â | Â | 0.11 |
 De novo | 187 (96%) | 57 (100%) | 130 (94%) |  |
 Secondary | 8 (4.1%) | 0 (0%) | 8 (5.8%) |  |
Ikarosplus, n (%) | 41 (27%) | 24 (51%) | 17 (16%) | <0.001 |
Protocol, n (%) | Â | Â | Â | 0.53 |
 LAL2317 | 109 (55%) | 30 (27.2%) | 79 (72.57%) |  |
 LAL1913 | 88 (45%) | 28 (31.8%) | 60 (68.2%) |  |